CEL-SCI logo

CVM - CEL-SCI Share Price

$11.36 -0.1  -0.7%

Last Trade - 26/10/21

Mid Cap
Market Cap £355.7m
Enterprise Value £331.7m
Revenue £20.7k
Position in Universe 3746th / 7274
Unlock CVM Revenue
Relative Strength (%)
1m -6.41%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -72.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Sep 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.66 0.29 0.069 0.48 0.46 0.56 0.10 0.40 -3.2%
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 June 2021, CEL-SCICorporation revenues decreased from $530K to $0K. Net lossapplicable to common stockholders increased 14% to $28.5M.Revenues reflect a decrease in demand for the Company'sproducts and services due to unfavorable market conditions.Higher net loss reflects $445,710, $438,738 and $434,030respecti increase of 41% to $17.8M (expense), General &administrative increase of 18% to $9.9M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


CVM Revenue Unlock CVM Revenue

Net Income

CVM Net Income Unlock CVM Revenue

Normalised EPS

CVM Normalised EPS Unlock CVM Revenue

PE Ratio Range

CVM PE Ratio Range Unlock CVM Revenue

Dividend Yield Range

CVM Dividend Yield Range Unlock CVM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
CVM EPS Forecasts Unlock CVM Revenue
Profile Summary

CEL-SCI Corp is a clinical-stage biotechnology company. The Company is focused on activating the immune system to fight cancer and infectious diseases. The Company is engaged in research and developing the treatments for the cancer and other diseases by using the immune system. The Company’s lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is in a pivotal Phase 3 clinical trial. Its Multikine is an investigational immunotherapy under development for the potential treatment of certain head and neck cancers. The Company using its Ligand Epitope Antigen Presentation System (LEAPS) technology platform is investigating product candidates include CEL-2000 and CEL-4000. CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis. It is also investigating LEAPS COVID-19 conjugates as a potential treatment of coronavirus (COVID-19) in hospitalized and at-high-risk patients at the University of Georgia’s (UGA) Center.

Last Annual September 30th, 2020
Last Interim June 30th, 2021
Incorporated March 22, 1983
Public Since December 8, 1983
No. of Shareholders: 617
No. of Employees: 43
Sector Healthcare
Industry Pharmaceuticals
Exchange NYSE MKT
Shares in Issue 43,028,150
Free Float (0.0%)
Eligible for
CVM Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CVM
Upcoming Events for CVM
Tuesday 28th December, 2021 Estimate
Q4 2021 CEL-SCI Corp Earnings Release
Monday 14th February, 2022 Estimate
Q1 2022 CEL-SCI Corp Earnings Release
Frequently Asked Questions for CEL-SCI
What is the CEL-SCI share price?

As of 26/10/21, shares in CEL-SCI are trading at $11.36, giving the company a market capitalisation of £355.7m. This share price information is delayed by 15 minutes.

How has the CEL-SCI share price performed this year?

Shares in CEL-SCI are currently trading at $11.36 and the price has moved by -12.74% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the CEL-SCI price has moved by -34.7% over the past year.

What are the analyst and broker recommendations for CEL-SCI?

Of the analysts with advisory recommendations for CEL-SCI, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for CEL-SCI is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will CEL-SCI next release its financial results?

CEL-SCI is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-06-30
What is the CEL-SCI dividend yield?

CEL-SCI does not currently pay a dividend.

Does CEL-SCI pay a dividend?

CEL-SCI does not currently pay a dividend.

When does CEL-SCI next pay dividends?

CEL-SCI does not currently pay a dividend.

How do I buy CEL-SCI shares?

To buy shares in CEL-SCI you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of CEL-SCI?

Shares in CEL-SCI are currently trading at $11.36, giving the company a market capitalisation of £355.7m.

Where are CEL-SCI shares listed? Where are CEL-SCI shares listed?

Here are the trading details for CEL-SCI:

Country of listing: United States
Exchange: ASQ
Ticker Symbol: CVM
What kind of share is CEL-SCI?

Based on an overall assessment of its quality, value and momentum, CEL-SCI is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a CEL-SCI share price forecast 2021?

Shares in CEL-SCI are currently priced at $11.36. At that level they are trading at 5.45% discount to the analyst consensus target price of 0.00.

Analysts covering CEL-SCI currently have a consensus Earnings Per Share (EPS) forecast of -0.23 for the next financial year.

How can I tell whether the CEL-SCI share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CEL-SCI. Over the past six months, the relative strength of its shares against the market has been -58.72%. At the current price of $11.36, shares in CEL-SCI are trading at -27.75% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the CEL-SCI PE Ratio?

We were not able to find PE ratio data for CEL-SCI.

Who are the key directors of CEL-SCI?

CEL-SCI's management team is headed by:

Geert Kersten - CEO
Patricia Prichep - SVP
Eyal Talor - CSO
Daniel Zimmerman - SVP
Peter Young - IND
John Cipriano - SVP
Robert Watson - IND
Bruno Baillavoine - IND
Who are the major shareholders of CEL-SCI?

Here are the top five shareholders of CEL-SCI based on the size of their shareholding:

State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 10.64% (4.58m shares)
SPDR S&P Biotech ETF Mutual Fund
Percentage owned: 8.67% (3.73m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 5.95% (2.56m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 4.8% (2.07m shares)
Kersten (Geert R) Individual Investor
Percentage owned: 2.61% (1.12m shares)
Similar to CVM
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.